Eli Lilly's experimental GLP-1 drug achieves 28% average weight loss, raising safety questions
By
Christopher Rowland
Summary
Eli Lilly has released data showing its experimental GLP-1 weight-loss drug enables patients to lose an average of 28% of their body weight, significantly more than existing GLP-1 medications. The article raises questions about the potential risks and limits of such powerful weight-loss interventions.
Source
bskyEli Lilly's experimental GLP-1 drug achieves 28% average weight loss, raising safety questionswashingtonpost.comKey quotes
· 3 pulledEli Lilly this month unveiled startling new data that showed an experimental weight-loss drug caused people with obesity to shed, on average, 28 percent of their body weight
a substantial step up in potency from the existing crop of GLP-1 medicines
But how much weight loss is too much?
You might also wanna read
Study: Most Patients Regain Weight and Lose Health Benefits After Stopping GLP-1 Drugs
A study on tirzepatide (a GLP-1 drug) found that after stopping the medication, 82% of participants regained at least 25% of the weight they
arstechnica.com·7mo ago
FDA Approves Foundayo (orforglipron): The First Oral GLP-1 Weight Loss Pill Without Fasting Requirements
The FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill by Eli Lilly, on April 1, 2026. Unlike other oral GLP
Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price t
theguardian.com·6mo ago
Daily weight loss pill available in UK pharmacies from today
Study: Over Half of Binge Eating Disorder Patients Have Used GLP-1 Weight-Loss Drugs
A study published in JAMA Psychiatry reveals that over half of patients with binge eating disorder and one-third with atypical anorexia nerv
mdsc.pe·9d ago
Tirzepatide
twc.health·8d agoTirzepatide
twc.health·8d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.